PEN - Penumbra, Inc.

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $320.00 DETAILS

Stock News

Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)

BOLT-DVT, a recent prospective, multicenter Investigational Device Exemption (IDE) trial, demonstrated first-line use of computer assisted vacuum thrombectomy (CAVT) for DVT is safe and effective ALAMEDA, Calif., Oct. 20, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the treatment of deep vein thrombosis (DVT) to the company's Lightning™ computer assisted vacuum thrombectomy (CAVT™) technology.

Oct 20, 2026 05:00 AM • prnewswire.com

Penumbra (NYSE:PEN) Stock Breaks Above 50-Day Moving Average – Should You Sell?

Penumbra, Inc. (NYSE: PEN - Get Free Report)'s share price passed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $321.17 and traded as high as $322.80. Penumbra shares last traded at $320.9220, with a volume of 278,513 shares. Wall Street Analysts Forecast Growth Several research

Oct 16, 2026 11:21 PM • defenseworld.net

New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism

Wearable-derived data provide new insights into how clinical outcomes for patients treated with CAVT and anticoagulation, and anticoagulation alone translate to patients' everyday recovery ALAMEDA, Calif., Oct. 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced results from a subset analysis of the landmark STORM-PE randomized controlled trial (RCT), the first trial to demonstrate a significant correlation between real-world, daily step-based activity as captured on a consumer wearable device and patient performance in the clinical 6-minute walk test.

Oct 06, 2026 05:00 AM • prnewswire.com

IART vs. PEN: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integra LifeSciences (IART) and Penumbra (PEN). But which of these two stocks offers value investors a better bang for their buck right now?

Oct 01, 2026 08:41 AM • zacks.com

Penumbra (NYSE:PEN) Stock Price Breaks Below Fifty Day Moving Average – What’s Next?

Penumbra, Inc. (NYSE: PEN - Get Free Report)'s stock price crossed below its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $321.74 and traded as low as $318.14. Penumbra shares last traded at $318.7630, with a volume of 186,317 shares changing hands. Wall Street Analyst Weigh In

Sep 29, 2026 10:42 PM • defenseworld.net

IART or PEN: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integra LifeSciences (IART) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?

Sep 29, 2026 08:41 AM • zacks.com

Reasons to Retain Penumbra Stock in Your Portfolio for Now

PEN's portfolio expansion and international growth support momentum, while rising costs, FX exposure and margin pressure remain key risks.

Sep 16, 2026 06:15 AM • zacks.com

TFX vs. PEN: Which Stock Is the Better Value Option?

Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two stocks is more attractive to value investors?

Sep 11, 2026 08:40 AM • zacks.com

Connor Clark & Lunn Investment Management Ltd. Buys New Position in Penumbra, Inc. $PEN

Connor Clark and Lunn Investment Management Ltd. purchased a new position in shares of Penumbra, Inc. (NYSE: PEN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 5,111 shares of the company's stock, valued at approximately $1,614,000. A number of other institutional

Aug 30, 2026 12:23 AM • defenseworld.net

TFX or PEN: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?

Aug 26, 2026 08:41 AM • zacks.com

TFX vs. PEN: Which Stock Is the Better Value Option?

Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?

Aug 10, 2026 08:41 AM • zacks.com

Penumbra, Inc. Reports Second Quarter 2026 Financial Results

ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026.

Jul 30, 2026 12:05 PM • prnewswire.com

Bank of Nova Scotia Acquires 210,402 Shares of Penumbra, Inc. $PEN

Bank of Nova Scotia boosted its stake in Penumbra, Inc. (NYSE: PEN) by 14,837.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 211,820 shares of the company's stock after purchasing an additional 210,402 shares during the quarter. Bank

Jul 25, 2026 12:05 AM • defenseworld.net

California Public Employees Retirement System Increases Position in Penumbra, Inc. $PEN

California Public Employees Retirement System lifted its stake in shares of Penumbra, Inc. (NYSE: PEN) by 25.1% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 60,421 shares of the company's stock after purchasing an additional 12,108 shares during

Jul 22, 2026 11:41 PM • defenseworld.net

THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care

THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care PR Newswire ALAMEDA, Cal

Jul 22, 2026 11:00 AM • gurufocus.com

THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care

First and only CAVT device for stroke demonstrated high revascularization rates, short procedure times and low complication rates ALAMEDA, Calif., July 22, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company's novel computer assisted vacuum thrombectomy (CAVT™) system, in stroke patients with emergent large vessel occlusion (ELVO).

Jul 22, 2026 10:35 AM • prnewswire.com

Penumbra, Inc. $PEN Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp decreased its stake in shares of Penumbra, Inc. (NYSE: PEN) by 0.9% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 246,527 shares of the company's stock after selling 2,129 shares during the

Jul 21, 2026 11:40 PM • defenseworld.net

3 Medical Device Stocks Giving Investors a Different Healthcare Play

When investors think of the health care sector, most imagine the stability of pharmaceutical giants or the high-risk/high-reward profile of up-and-coming clinical stage drug developers. Medical device companies operate within a unique ecosystem and are often easy to overlook.

Jul 20, 2026 05:40 AM • marketbeat.com

IQV vs. PEN: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical - Instruments sector have probably already heard of IQVIA Holdings (IQV) and Penumbra (PEN). But which of these two stocks is more attractive to value investors?

Jul 14, 2026 08:40 AM • zacks.com

First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke

ALAMEDA, Calif., July 7, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the initiation of its FORWARD study, an international, real world prospective, multi-center study.

Jul 07, 2026 05:00 AM • prnewswire.com

Price Targets

PEN - Penumbra, Inc.

Stock News

Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)

Penumbra (NYSE:PEN) Stock Breaks Above 50-Day Moving Average – Should You Sell?

New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism

IART vs. PEN: Which Stock Is the Better Value Option?

Penumbra (NYSE:PEN) Stock Price Breaks Below Fifty Day Moving Average – What’s Next?

IART or PEN: Which Is the Better Value Stock Right Now?

Reasons to Retain Penumbra Stock in Your Portfolio for Now

TFX vs. PEN: Which Stock Is the Better Value Option?

Connor Clark & Lunn Investment Management Ltd. Buys New Position in Penumbra, Inc. $PEN

TFX or PEN: Which Is the Better Value Stock Right Now?

TFX vs. PEN: Which Stock Is the Better Value Option?

Penumbra, Inc. Reports Second Quarter 2026 Financial Results

Bank of Nova Scotia Acquires 210,402 Shares of Penumbra, Inc. $PEN

California Public Employees Retirement System Increases Position in Penumbra, Inc. $PEN

THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care

THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care

Penumbra, Inc. $PEN Shares Sold by Bank of New York Mellon Corp

3 Medical Device Stocks Giving Investors a Different Healthcare Play

IQV vs. PEN: Which Stock Is the Better Value Option?

First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke

Price Targets

Penumbra price target lowered to $320 from $335 at Evercore ISI

Penumbra price target lowered to $335 from $345 at Evercore ISI

UBS Reiterates Neutral Rating on Penumbra (PEN) Following Q4 Results

Penumbra price target raised to $360 from $340 at Evercore ISI

Penumbra downgraded to Sector Perform from Outperform at RBC Capital

Penumbra downgraded to Hold from Buy at Canaccord

Penumbra downgraded to Hold from Buy at Jefferies

Baird Downgrades Penumbra (PEN) to Neutral

Leerink Partners Downgrades Penumbra (PEN) to Market Perform

Truist Securities Downgrades Penumbra (PEN) to Hold

Penumbra downgraded to Neutral from Buy at BTIG

Penumbra downgraded to Equal Weight from Overweight at Wells Fargo

Penumbra downgraded to Neutral from Overweight at Piper Sandler

Penumbra price target raised to $340 from $286 at Evercore ISI

Penumbra price target raised to $370 from $312 at Truist

Penumbra price target raised to $355 from $325 at RBC Capital

Penumbra price target raised to $359 from $355 at Canaccord

Penumbra (PEN) PT Raised to $388 at Needham

Penumbra price target raised to $345 from $310 at Baird

Penumbra price target raised to $286 from $285 at Evercore ISI